Array BioPharma Inc.s in-depth stock price analysis indicates that the stock price has rallied 51.2% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 270.06% . Looking at the past 52 week period, the stock price is up at 357.63% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of Array BioPharma Inc. has a positive value of 197.97 compared to overall market. Array BioPharma Inc. (NASDAQ:ARRY) has climbed 11.43% in the past week and advanced 10.3% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 10.53% and the outperformance has advanced to 8.33% for the last 4 weeks period.
Array BioPharma Inc. (NASDAQ:ARRY) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.57 points or 4.54% at $11.99 with 9,622,826 shares getting traded. Post opening the session at $12.92, the shares hit an intraday low of $11.79 and an intraday high of $13.4 and the price was in this range throughout the day. The company has a market cap of $2,026 million and the number of outstanding shares has been calculated to be 169,007,250 shares. The 52-week high of Array BioPharma Inc. (NASDAQ:ARRY) is $13.4 and the 52-week low is $2.385.
Array Biopharma Inc Last issued its quarterly earnings results on Feb 9, 2017. The company reported $-0.14 EPS for the quarter, beating the analyst consensus estimate by $ 0.06. Analyst had a consensus of $-0.20. The company had revenue of $44.50 million for the quarter, compared to analysts expectations of $34.58 million. The companys revenue was up 25.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.17 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Array Biopharma Inc was Downgraded by JP Morgan to Neutral on Feb 3, 2017. Company shares were Reiterated by Stifel on Feb 3, 2017 to Buy, Raises Price Target to $ 13 from a previous price target of $8 .Array Biopharma Inc was Downgraded by Leerink Partners to Mkt Perform on Jan 30, 2017.
Company has reported several Insider transactions to the SEC, on May 12, 2015, Charles M Baum (director) sold 25,000 shares at 7.38 per share price.On Mar 4, 2015, Kyle Lefkoff (director) sold 70,000 shares at 8.00 per share price.On Mar 4, 2015, Andrews R Robbins (SVP, Commercial Operations) sold 21,576 shares at 8.25 per share price.
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The companys proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas.